Supplemental Table 5 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Article Swipe

PDF

Wenjie Xiong , Yuting Yan , Tingyu Wang , Weiwei Sui , Ying Yu , Tengteng Yu , Rui Lyu , Yi Wang , Wei Liu , Huimin Liu , Gang An , Yan Xu , Wenyang Huang , Dehui Zou , Lugui Qiu , Shuhua Yi ·

YOU? · · 2025 · Open Access · · DOI: https://doi.org/10.1158/1078-0432.29072467

Supplemental Table 5. Factors associated with progression.

Related Topics

Concepts

Dexamethasone Medicine Macroglobulinemia Ixazomib Waldenstrom macroglobulinemia Internal medicine Dermatology Multiple myeloma Lenalidomide Lymphoma Carfilzomib

Metadata

Type: preprint
Language: en
Landing Page: https://doi.org/10.1158/1078-0432.29072467
PDF: https://aacr.figshare.com/articles/journal_contribution/Supplemental_Table_5_from_Zanubrutinib_plus_Ixazomib_and_Dexamethasone_in_Newly_Diagnosed_Symptomatic_Waldenstr_m_Macroglobulinemia_A_Phase_II_Study/29072467/1/files/54563410.pdf
OA Status: gold
Related Works: 10
OpenAlex ID: https://openalex.org/W4410402377

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4410402377

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1158/1078-0432.29072467

Digital Object Identifier
Title: Supplemental Table 5 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study

Work title
Type: preprint

OpenAlex work type
Language: en

Primary language
Publication year: 2025

Year of publication
Publication date: 2025-05-15

Full publication date if available
Authors: Wenjie Xiong, Yuting Yan, Tingyu Wang, Weiwei Sui, Ying Yu, Tengteng Yu, Rui Lyu, Yi Wang, Wei Liu, Huimin Liu, Gang An, Yan Xu, Wenyang Huang, Dehui Zou, Lugui Qiu, Shuhua Yi

List of authors in order
Landing page: https://doi.org/10.1158/1078-0432.29072467

Publisher landing page
PDF URL: https://aacr.figshare.com/articles/journal_contribution/Supplemental_Table_5_from_Zanubrutinib_plus_Ixazomib_and_Dexamethasone_in_Newly_Diagnosed_Symptomatic_Waldenstr_m_Macroglobulinemia_A_Phase_II_Study/29072467/1/files/54563410.pdf

Direct link to full text PDF
Open access: Yes

Whether a free full text is available
OA status: gold

Open access status per OpenAlex
OA URL: https://aacr.figshare.com/articles/journal_contribution/Supplemental_Table_5_from_Zanubrutinib_plus_Ixazomib_and_Dexamethasone_in_Newly_Diagnosed_Symptomatic_Waldenstr_m_Macroglobulinemia_A_Phase_II_Study/29072467/1/files/54563410.pdf

Direct OA link when available
Concepts: Dexamethasone, Medicine, Macroglobulinemia, Ixazomib, Waldenstrom macroglobulinemia, Internal medicine, Dermatology, Multiple myeloma, Lenalidomide, Lymphoma, Carfilzomib

Top concepts (fields/topics) attached by OpenAlex
Cited by: 0

Total citation count in OpenAlex
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W4410402377
doi	https://doi.org/10.1158/1078-0432.29072467
ids.doi	https://doi.org/10.1158/1078-0432.29072467
ids.openalex	https://openalex.org/W4410402377
fwci	0.0
type	preprint
title	Supplemental Table 5 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
topics[0].id	https://openalex.org/T11157
topics[0].field.id	https://openalex.org/fields/27
topics[0].field.display_name	Medicine
topics[0].score	0.9994999766349792
topics[0].domain.id	https://openalex.org/domains/4
topics[0].domain.display_name	Health Sciences
topics[0].subfield.id	https://openalex.org/subfields/2716
topics[0].subfield.display_name	Genetics
topics[0].display_name	Chronic Lymphocytic Leukemia Research
topics[1].id	https://openalex.org/T11215
topics[1].field.id	https://openalex.org/fields/27
topics[1].field.display_name	Medicine
topics[1].score	0.9490000009536743
topics[1].domain.id	https://openalex.org/domains/4
topics[1].domain.display_name	Health Sciences
topics[1].subfield.id	https://openalex.org/subfields/2720
topics[1].subfield.display_name	Hematology
topics[1].display_name	Chronic Myeloid Leukemia Treatments
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C2780401358
concepts[0].level	2
concepts[0].score	0.7008126378059387
concepts[0].wikidata	https://www.wikidata.org/wiki/Q422252
concepts[0].display_name	Dexamethasone
concepts[1].id	https://openalex.org/C71924100
concepts[1].level	0
concepts[1].score	0.5645899176597595
concepts[1].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[1].display_name	Medicine
concepts[2].id	https://openalex.org/C2776391228
concepts[2].level	3
concepts[2].score	0.5630046725273132
concepts[2].wikidata	https://www.wikidata.org/wiki/Q4118092
concepts[2].display_name	Macroglobulinemia
concepts[3].id	https://openalex.org/C2781098529
concepts[3].level	5
concepts[3].score	0.48487409949302673
concepts[3].wikidata	https://www.wikidata.org/wiki/Q20948663
concepts[3].display_name	Ixazomib
concepts[4].id	https://openalex.org/C2781038049
concepts[4].level	3
concepts[4].score	0.43977272510528564
concepts[4].wikidata	https://www.wikidata.org/wiki/Q1778287
concepts[4].display_name	Waldenstrom macroglobulinemia
concepts[5].id	https://openalex.org/C126322002
concepts[5].level	1
concepts[5].score	0.3350624442100525
concepts[5].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[5].display_name	Internal medicine
concepts[6].id	https://openalex.org/C16005928
concepts[6].level	1
concepts[6].score	0.3201392889022827
concepts[6].wikidata	https://www.wikidata.org/wiki/Q171171
concepts[6].display_name	Dermatology
concepts[7].id	https://openalex.org/C2776364478
concepts[7].level	2
concepts[7].score	0.23421505093574524
concepts[7].wikidata	https://www.wikidata.org/wiki/Q467635
concepts[7].display_name	Multiple myeloma
concepts[8].id	https://openalex.org/C2776063141
concepts[8].level	3
concepts[8].score	0.06893017888069153
concepts[8].wikidata	https://www.wikidata.org/wiki/Q425681
concepts[8].display_name	Lenalidomide
concepts[9].id	https://openalex.org/C2779338263
concepts[9].level	2
concepts[9].score	0.0
concepts[9].wikidata	https://www.wikidata.org/wiki/Q208414
concepts[9].display_name	Lymphoma
concepts[10].id	https://openalex.org/C2780108899
concepts[10].level	4
concepts[10].score	0.0
concepts[10].wikidata	https://www.wikidata.org/wiki/Q15366934
concepts[10].display_name	Carfilzomib
keywords[0].id	https://openalex.org/keywords/dexamethasone
keywords[0].score	0.7008126378059387
keywords[0].display_name	Dexamethasone
keywords[1].id	https://openalex.org/keywords/medicine
keywords[1].score	0.5645899176597595
keywords[1].display_name	Medicine
keywords[2].id	https://openalex.org/keywords/macroglobulinemia
keywords[2].score	0.5630046725273132
keywords[2].display_name	Macroglobulinemia
keywords[3].id	https://openalex.org/keywords/ixazomib
keywords[3].score	0.48487409949302673
keywords[3].display_name	Ixazomib
keywords[4].id	https://openalex.org/keywords/waldenstrom-macroglobulinemia
keywords[4].score	0.43977272510528564
keywords[4].display_name	Waldenstrom macroglobulinemia
keywords[5].id	https://openalex.org/keywords/internal-medicine
keywords[5].score	0.3350624442100525
keywords[5].display_name	Internal medicine
keywords[6].id	https://openalex.org/keywords/dermatology
keywords[6].score	0.3201392889022827
keywords[6].display_name	Dermatology
keywords[7].id	https://openalex.org/keywords/multiple-myeloma
keywords[7].score	0.23421505093574524
keywords[7].display_name	Multiple myeloma
keywords[8].id	https://openalex.org/keywords/lenalidomide
keywords[8].score	0.06893017888069153
keywords[8].display_name	Lenalidomide
language	en
locations[0].id	doi:10.1158/1078-0432.29072467
locations[0].is_oa	True
locations[0].source
locations[0].license	cc-by
locations[0].pdf_url	https://aacr.figshare.com/articles/journal_contribution/Supplemental_Table_5_from_Zanubrutinib_plus_Ixazomib_and_Dexamethasone_in_Newly_Diagnosed_Symptomatic_Waldenstr_m_Macroglobulinemia_A_Phase_II_Study/29072467/1/files/54563410.pdf
locations[0].version	acceptedVersion
locations[0].raw_type	posted-content
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	True
locations[0].is_published	False
locations[0].raw_source_name
locations[0].landing_page_url	https://doi.org/10.1158/1078-0432.29072467
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5002560631
authorships[0].author.orcid	https://orcid.org/0000-0002-0302-0408
authorships[0].author.display_name	Wenjie Xiong
authorships[0].author_position	first
authorships[0].raw_author_name	Wenjie Xiong
authorships[0].is_corresponding	False
authorships[1].author.id	https://openalex.org/A5074352094
authorships[1].author.orcid	https://orcid.org/0000-0002-9355-2984
authorships[1].author.display_name	Yuting Yan
authorships[1].author_position	middle
authorships[1].raw_author_name	Yuting Yan
authorships[1].is_corresponding	False
authorships[2].author.id	https://openalex.org/A5046420041
authorships[2].author.orcid	https://orcid.org/0000-0003-4542-3587
authorships[2].author.display_name	Tingyu Wang
authorships[2].author_position	middle
authorships[2].raw_author_name	Tingyu Wang
authorships[2].is_corresponding	False
authorships[3].author.id	https://openalex.org/A5083334234
authorships[3].author.orcid	https://orcid.org/0000-0002-6982-8258
authorships[3].author.display_name	Weiwei Sui
authorships[3].author_position	middle
authorships[3].raw_author_name	Weiwei Sui
authorships[3].is_corresponding	False
authorships[4].author.id	https://openalex.org/A5101397220
authorships[4].author.orcid	https://orcid.org/0000-0001-7362-2925
authorships[4].author.display_name	Ying Yu
authorships[4].author_position	middle
authorships[4].raw_author_name	Ying Yu
authorships[4].is_corresponding	False
authorships[5].author.id	https://openalex.org/A5103244427
authorships[5].author.orcid	https://orcid.org/0000-0003-4005-3003
authorships[5].author.display_name	Tengteng Yu
authorships[5].author_position	middle
authorships[5].raw_author_name	Tengteng Yu
authorships[5].is_corresponding	False
authorships[6].author.id	https://openalex.org/A5001940334
authorships[6].author.orcid	https://orcid.org/0000-0003-0302-7615
authorships[6].author.display_name	Rui Lyu
authorships[6].author_position	middle
authorships[6].raw_author_name	Rui Lyu
authorships[6].is_corresponding	False
authorships[7].author.id	https://openalex.org/A5002754835
authorships[7].author.orcid	https://orcid.org/0000-0002-0066-1234
authorships[7].author.display_name	Yi Wang
authorships[7].author_position	middle
authorships[7].raw_author_name	Yi Wang
authorships[7].is_corresponding	False
authorships[8].author.id	https://openalex.org/A5100431728
authorships[8].author.orcid	https://orcid.org/0000-0002-0448-7210
authorships[8].author.display_name	Wei Liu
authorships[8].author_position	middle
authorships[8].raw_author_name	Wei Liu
authorships[8].is_corresponding	False
authorships[9].author.id	https://openalex.org/A5115588015
authorships[9].author.orcid	https://orcid.org/0000-0001-7681-1326
authorships[9].author.display_name	Huimin Liu
authorships[9].author_position	middle
authorships[9].raw_author_name	Huimin Liu
authorships[9].is_corresponding	False
authorships[10].author.id	https://openalex.org/A5027278571
authorships[10].author.orcid	https://orcid.org/0000-0003-4922-4614
authorships[10].author.display_name	Gang An
authorships[10].author_position	middle
authorships[10].raw_author_name	Gang An
authorships[10].is_corresponding	False
authorships[11].author.id	https://openalex.org/A5100331702
authorships[11].author.orcid	https://orcid.org/0000-0002-6167-3319
authorships[11].author.display_name	Yan Xu
authorships[11].author_position	middle
authorships[11].raw_author_name	Yan Xu
authorships[11].is_corresponding	False
authorships[12].author.id	https://openalex.org/A5114241507
authorships[12].author.orcid
authorships[12].author.display_name	Wenyang Huang
authorships[12].author_position	middle
authorships[12].raw_author_name	Wenyang Huang
authorships[12].is_corresponding	False
authorships[13].author.id	https://openalex.org/A5017214725
authorships[13].author.orcid	https://orcid.org/0000-0002-8135-4913
authorships[13].author.display_name	Dehui Zou
authorships[13].author_position	middle
authorships[13].raw_author_name	Dehui Zou
authorships[13].is_corresponding	False
authorships[14].author.id	https://openalex.org/A5017804632
authorships[14].author.orcid	https://orcid.org/0000-0002-8752-0644
authorships[14].author.display_name	Lugui Qiu
authorships[14].author_position	middle
authorships[14].raw_author_name	Lugui Qiu
authorships[14].is_corresponding	False
authorships[15].author.id	https://openalex.org/A5030715375
authorships[15].author.orcid	https://orcid.org/0000-0002-6291-812X
authorships[15].author.display_name	Shuhua Yi
authorships[15].author_position	last
authorships[15].raw_author_name	Shuhua Yi
authorships[15].is_corresponding	False
has_content.pdf	True
has_content.grobid_xml	True
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://aacr.figshare.com/articles/journal_contribution/Supplemental_Table_5_from_Zanubrutinib_plus_Ixazomib_and_Dexamethasone_in_Newly_Diagnosed_Symptomatic_Waldenstr_m_Macroglobulinemia_A_Phase_II_Study/29072467/1/files/54563410.pdf
open_access.oa_status	gold
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	Supplemental Table 5 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
has_fulltext	False
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T11157
primary_topic.field.id	https://openalex.org/fields/27
primary_topic.field.display_name	Medicine
primary_topic.score	0.9994999766349792
primary_topic.domain.id	https://openalex.org/domains/4
primary_topic.domain.display_name	Health Sciences
primary_topic.subfield.id	https://openalex.org/subfields/2716
primary_topic.subfield.display_name	Genetics
primary_topic.display_name	Chronic Lymphocytic Leukemia Research
related_works	https://openalex.org/W2040015650, https://openalex.org/W2981964593, https://openalex.org/W2142199742, https://openalex.org/W155378922, https://openalex.org/W3151943896, https://openalex.org/W2000967713, https://openalex.org/W2552000281, https://openalex.org/W2058941576, https://openalex.org/W2895466941, https://openalex.org/W2140380015
cited_by_count	0
locations_count	1
best_oa_location.id	doi:10.1158/1078-0432.29072467
best_oa_location.is_oa	True
best_oa_location.source
best_oa_location.license	cc-by
best_oa_location.pdf_url	https://aacr.figshare.com/articles/journal_contribution/Supplemental_Table_5_from_Zanubrutinib_plus_Ixazomib_and_Dexamethasone_in_Newly_Diagnosed_Symptomatic_Waldenstr_m_Macroglobulinemia_A_Phase_II_Study/29072467/1/files/54563410.pdf
best_oa_location.version	acceptedVersion
best_oa_location.raw_type	posted-content
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	True
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url	https://doi.org/10.1158/1078-0432.29072467
primary_location.id	doi:10.1158/1078-0432.29072467
primary_location.is_oa	True
primary_location.source
primary_location.license	cc-by
primary_location.pdf_url	https://aacr.figshare.com/articles/journal_contribution/Supplemental_Table_5_from_Zanubrutinib_plus_Ixazomib_and_Dexamethasone_in_Newly_Diagnosed_Symptomatic_Waldenstr_m_Macroglobulinemia_A_Phase_II_Study/29072467/1/files/54563410.pdf
primary_location.version	acceptedVersion
primary_location.raw_type	posted-content
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	True
primary_location.is_published	False
primary_location.raw_source_name
primary_location.landing_page_url	https://doi.org/10.1158/1078-0432.29072467
publication_date	2025-05-15
publication_year	2025
referenced_works_count	0
abstract_inverted_index.5.	2
abstract_inverted_index.with	5
abstract_inverted_index.Table	1
abstract_inverted_index.Factors	3
abstract_inverted_index.associated	4
abstract_inverted_index.<p>Supplemental	0
abstract_inverted_index.progression.</p>	6
cited_by_percentile_year
countries_distinct_count	0
institutions_distinct_count	16
citation_normalized_percentile.value	0.24138301
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	False